United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

According to a real-world data study in Israel, the coronavirus variant discovered in South Africa may dodge the protection provided by Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine to some extent. It is also noted that the South African variant, B.1.351, made up about 1% of all the COVID-19 cases across all the people studied in the country, and the research has not been peer-reviewed.

South African Variant Able To Elude Pfizer/BioNTech' Vaccine Protection, Israeli Study Shows: Report

AstraZeneca

Johnson & Johnson

Moderna

Novavax

Regeneron Pharmaceuticals

Nearly everyone will get the Covid-19 vaccination, suggesting strong revenue for a handful of pharmaceutical companies. The post Vaccine Passport Potential Could Boost These 7 Pharmaceutical Stocks appeared first on InvestorPlace.

Vaccine Passport Potential Could Boost These 7 Pharmaceutical Stocks

Celcuity (CELC) is developing gedatolisib in combination with Pfizer's Ibrance and an endocrine therapy in breast cancer patients. It inks deal to gain exclusive rights to gedatolisib from Pfizer.

Celcuity (CELC) Soars on Agreement With Pfizer & Study Data

The big drugmaker's dividend won't remain at its current level for much longer.

Pfizer's About to Cut Its Dividend: What You Need to Know

The coronavirus variant first discovered in South Africa is able to evade some of the protection of the Pfizer-BioNTech vaccine, according to an Israeli study.

Covid variant from South Africa was able to ‘break through' Pfizer vaccine in Israeli study

Coronavirus variants first found in South Africa and the UK are able to partially "breakthrough" the Pfizer/BioNTech vaccine, according to an Israeli study that studied real-world infection data. The study has not yet been peer-reviewed. The study, released on Saturday, compared the incidences of both variants between vaccinated and unvaccinated patients who had tested positive for the coronavirus. The study, conducted by Tel Aviv University and Israeli healthcare provider Clalit tracked almost 400 people, and counted both partially vaccinated (one dose) and fully vaccinated (two dose) patients.

Pfizer vaccine may be less effective against South African and UK coronavirus variants, according to Israeli study

AbbVie

Brookfield Renewable Partners

These stocks check off all the boxes for dividend-seeking investors.

3 Great Dividend Stocks to Buy Right Now

Hims & Hers Health

111 Inc - ADR

These companies are at the forefront of innovation in the healthcare sector, and their stocks are surprisingly affordable too.

3 Top Healthcare Growth Stocks to Buy for April

Pharmaceutical giant Pfizer announced on Friday that it submitted a request for emergency use authorization to begin administering its COVID-19 vaccine to adolescents between the ages of 12 and 15 in the U.S.

Pfizer requests emergency use authorization to administer COVID-19 vaccine to adolescents

Pfizer has transformed itself into a growth stock, even without the Covid-19 boost. Here's what you should know about PFE stock.

Pfizer Has a Lumpy Growth Story, But It's a Promising Investment

The request comes just days after Pfizer released clinical trial data demonstrating its vaccine was 100% effective and well tolerated by the younger age group.

Pfizer asks FDA to clear its COVID-19 vaccine for use in kids ages 12 to 15

Pfizer's shot could be the first coronavirus vaccine approved for 12- to 15-year-olds.

Pfizer Asks FDA To Approve Its Covid Vaccine For Younger Teenagers

The European Commission is reportedly seeking EU governments' approval to get into talks with Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) to purchase up to 1.8 billion doses of their COVID-19 vaccines to be delivered in 2022 and 2023, Reuters reported. Earlier today, German daily Die Welt reported that the Commission was to sign contracts shortly to buy up to 1.8 billion doses but did not say with which company.

European Union Looks To Buy 1.8B Pfizer-BioNTech COVID-19 Vaccine Doses From 2022: Reuters

Shares of Pfizer Inc. gained 1% in trading on Friday after the drug maker said it requested that the emergency-use authorization for its COVID-19 vaccine be amended to include teens between the ages of 12 and 15. The vaccine is currently authorized for people who are at least 16 years old in the U.S. Pfizer said a Phase 3 clinical trial in 12- to 15-year-olds found that the vaccine is 100% efficacious and had a similar side-effect profile to past study participants between the ages of 16 and 25.

Pfizer asks FDA to expand COVID-19 vaccine authorization to include 12- to 15-year-olds

Pfizer and BioNTech and requested that US regulatory agencies to make their COVID-19 vaccine available for adolescents aged 12 to 15. In a press release issued on Friday, the companies said they plan to make similar requests worldwide in coming days.

Pfizer and BioNTech have asked US regulators to make their COVID-19 vaccine available to adolescents ages 12 to 15

Shares of Pfizer Inc. gained 1.0% in trading on Friday after the drug maker said it requested that the emergency authorization for its COVID-19 vaccine be amended to include teens between the ages of 12 and 15 years old. The vaccine is currently authorized for people who are at least 16 years old in the U.S. Pfizer said a Phase 3 clinical trial in 12 to 15 years old found that the vaccine is 100% efficacious and had a similar side-effect profile to past study participants between the ages of 16 to 25 years old.

Pfizer requests FDA expand authorization to include 12 to 15 year olds

ACADIA Pharma

Alexion Pharma

Biogen

CRISPR Therapeutics

Editas Medicine

Illumina

Kadmon Hlds

Regulatory and drug-pricing worries have knocked biotech stocks off their Covid-19 pedestal. After hitting a high point in early February, biotech stocks have collectedly fallen 21%.

Biotech Stocks Hit A Snag — Why Experts Say The Heyday Isn't Over

The FDA extends the review period of Pfizer's (PFE) candidate abrocitinib in atopic dermatitis by three months.

Pfizer (PFE) Dermatitis JAK Inhibitor NDA Review Gets Delayed

There are several potential reasons why investors didn't cheer the companies' great news more loudly.

Why Didn't Pfizer and BioNTech Stocks Soar After Their COVID Vaccine Achieved 100% Efficacy in Kids?

The National Institutes of Health (NIH) has begun a mid-stage study to determine the risk of allergic reactions shortly after receiving COVID-19 vaccines made by Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE)/BioNTech SE (NASDAQ: BNTX). Several allergic reaction incidents, including serious episodes known as anaphylaxis, have been reported in the U.S. after vaccinations of Pfizer/BioNTech and Moderna shots.

NIH Starts Study On Allergic Reactions Risk To Pfizer/BioNTech, Moderna COVID-19 Vaccines

Abercrombie & Fitch

Teva Pharmaceutical

Danaher

Flexion Therapeutics

Jazz Pharmaceuticals

With the trading day approaching halfway over, the broad markets were trading marginally positive.

Abercrombie, Pfizer, Teva and More of Wednesday Afternoon Analyst Calls

The NIH said it has begun looking at why some people have suffered from allergic reactions after receiving the Pfizer-BioNTech and Moderna Covid-19 vaccines.

U.S. begins study assessing allergic reactions to Pfizer and Moderna Covid vaccines

Canada's health regulator was launching a probe into Pfizer Inc's (NYSE: PFE) arthritis drug, Xeljanz and Xeljanz XR (tofacitinib), after a trial by the company identified an increased risk of serious heart-related issues and cancer in the participants. The trial investigated the long-term safety of Xeljanz at two doses in patients with rheumatoid arthritis, who are at least 50 years old and have at least one cardiovascular risk factor.

Pfizer's Xeljanz Under Health Canada's Scrutiny For Safety Risks

Shares of Pfizer Inc. were up 0.1% after the drug maker said regulators in the U.S. extended the priority review time for three months for two therapies: abrocitinib, a new treatment candidate for severe atopic dermatitis, and Xeljanz, an already approved drug aiming for a new indication for active ankylosing spondylitis. Pfizer's stock is down 2.0% since the start of the year, while the S&P 500 has gained 8.5%.

Pfizer says FDA review time for dermatitis drug candidate has been extended

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has extended the priority review period for the New Drug Application (NDA) for abrocitinib for the treatment of adults and adolescents with moderate to severe atopic dermatitis. The Prescription Drug User Fee Act (PDUFA) goal date has been extended three months to early Q3 2021. The FDA has also extended the review period for the Supplemental New Drug Applications (sNDAs) for XELJ

News for Pfizer Stock (PFE)